Synthesis, biological evaluation, and molecular docking study of pyridine clubbed 1,3,4-oxadiazoles as potential antituberculars

References

• Kwan, C. K.; Ernst, J. D. HIV and Tuberculosis: a Deadly Human Syndemic. Clin. Microbiol. Rev. 2011, 24, 351–376. DOI: 10.1128/cmr.00042-10.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report 2016; World Health Organization:Geneva, 2016.
   Google Scholar
• Abubakar, I.; Zignol, M.; Falzon, D.; Raviglione, M.; Ditiu, L.; Masham, S.; Adetifa, I.; Ford, N.; Cox, H.; Lawn S. D.; et al. Drug-Resistant Tuberculosis: Time for Visionary Political Leadership. Lancet Infect. Dis. 2013, 13, 529–539. DOI: 10.1016/s1473-3099(13)70030-6.
   PubMed Web of Science ®Google Scholar
• Lawn, S. D.; Mwaba, P.; Bates, M.; Piatek, A.; Alexander, H.; Marais, B. J.; Cuevas, L. E.; McHugh, T. D.; Zijenah, L.; Kapata, N.; et al. Advances in Tuberculosis Diagnostics: The Xpert MTB/RIF Assay and Future Prospects for a Point-of-Care Test. Lancet Infect. Dis. 2013, 13, 349–361. DOI: 10.1016/s1473-3099(13)70008-2.
   PubMed Web of Science ®Google Scholar
• Prabowo, S. A.; Gröschel, M. I.; Schmidt, E. D. L.; Skrahina, A.; Mihaescu, T.; Hastürk, S.; Mitrofanov, R.; Pimkina, E.; Visontai, I.; de Jong, B.; et al. Targeting Multidrug-Resistant Tuberculosis (MDR-TB) by Therapeutic Vaccines. Med. Microbiol. Immunol. 2013, 202, 95–104. DOI: 10.1007/s00430-012-0278-6.
   PubMed Web of Science ®Google Scholar
• Falzon, D.; Jaramillo, E.; Schünemann, H. J.; Arentz, M.; Bauer, M; Bayona, J.; Blanc, L.; Caminero, J. A.; Daley, C. L.; Duncombe, C.; et al. WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update. Eur. Respir. J. 2011, 38, 516–528. DOI: 10.1183/09031936.00073611.
   PubMed Web of Science ®Google Scholar
• Kumar, V.; Patel, S.; Jain, R. New Structural Classes of Antituberculosis Agents. Med. Res. Rev. 2017, 1–55. DOI: 10.1002/med.21454.
   Web of Science ®Google Scholar
• Nguyen, L.; Jacobs, M. R. Counterattacking Drug-Resistant Tuberculosis: Molecular Strategies and Future Directions. Expert. Rev. Anti. Infect. Ther. 2012, 10, 959–961. DOI: 10.1586/eri.12.97.
   Web of Science ®Google Scholar
• Nzila, A.; Ma, Z.; Chibale, K. Drug Repositioning in the Treatment of Malaria and TB. Future Med. Chem. 2011, 3, 1413–1426. DOI: 10.4155/fmc.11.95.
   PubMed Web of Science ®Google Scholar
• Dartois, V.; Barry C. E. A Medicinal Chemists’ Guide to the Unique Difficulties of Lead Optimization for Tuberculosis. Bioorg. Med. Chem. Lett. 2013, 23, 4741–4750. DOI: 10.1016/j.bmcl.2013.07.006.
   PubMed Web of Science ®Google Scholar
• Patani, G. A.; LaVoie, E. J. Bioisosterism: A Rational Approach in Drug Design. Chem. Rev. 1996, 96, 3147–3176. DOI: 10.1021/cr950066q.
   PubMed Web of Science ®Google Scholar
• Ziedan, N. I.; Hamdy, R.; Cavaliere, A.; Kourti, M.; Prencipe, F.; Brancale, A.; Jones, A. T.; Westwell, A. D. Virtual Screening, SAR, and Discovery of 5-(Indole-3-yl)-2-[(2-nitrophenyl)amino] [1,3,4]-Oxadiazole as a Novel Bcl-2 Inhibitor. Chem. Biol. Drug. Des. 2017, 90, 147–155. DOI: 10.1111/cbdd.12936.
   PubMed Web of Science ®Google Scholar
• Desai, N. C.; Bhatt, N.; Somani, H.; Trivedi, A. Synthesis, Antimicrobial and Cytotoxic Activities of Some Novel Thiazole Clubbed 1,3,4-Oxadiazoles. Eur. J. Med. Chem. 2013, 67, 54–59. DOI: 10.1016/j.ejmech.2013.06.029.
   PubMed Web of Science ®Google Scholar
• Khan, S. A.; Ahuja, P.; Husain, A. Oxidative Cyclization of Isoniazid with Fluoroquinolones: Synthesis, Antibacterial and Antitubercular Activity of New 2,5-Disubstituted-1,3,4-oxadiazoles. J. Chin. Chem. Soc. 2017, 64, 918–924. DOI: 10.1002/jccs.201600199.
   Web of Science ®Google Scholar
• Harish, K. P.; Mohana, K. N.; Mallesha, L.; Veeresh, B. Synthesis and In Vivo Anticonvulsant Activity of 2-Methyl-2-[3-(5-piperazin-1-yl-[1,3,4]oxadiazol-2-yl)-phenyl]-propionitrile Derivatives. Arch. Pharm. 2014, 347, 256–267. DOI: 10.1002/ardp.201300225.
   PubMed Web of Science ®Google Scholar
• Rajak, H.; Singh Thakur, B.; Singh, A.; Raghuvanshi, K.; Sah, A. K.; Veerasamy, R.; Sharma, P. C.; Singh Pawar, R.; Kharya, M. D. Novel Limonene and Citral Based 2,5-Disubstituted-1,3,4-oxadiazoles: A Natural Product Coupled Approach to Semicarbazones for Antiepileptic Activity. Bioorg. Med. Chem. Lett. 2013, 23, 864–868. DOI: 10.1016/j.bmcl.2012.11.051.
   PubMed Web of Science ®Google Scholar
• Li, Z.; Zhan, P.; Liu, X. 1,3,4-Oxadiazole: A Privileged Structure in Antiviral Agents. Mini. Rev. Med. Chem. 2011, 11, 1130–1142. DOI: 10.2174/138955711797655407.
   PubMed Web of Science ®Google Scholar
• Guda, D. R.; Park, S.-J.; Lee, M.-W.; Kim, T.-J.; Lee, M. E. Syntheses and Anti-Allergic Activity of 2-((Bis(trimethylsilyl)methylthio/methylsulfonyl)methyl)-5-aryl-1,3,4-oxadiazoles. Eur. J. Med. Chem. 2013, 62, 84–88. DOI: 10.1016/j.ejmech.2012.12.035.
   PubMed Web of Science ®Google Scholar
• Boström, J.; Hogner, A.; Llinàs, A.; Wellner, E.; Plowright, A. T. Oxadiazoles in Medicinal Chemistry. J. Med. Chem. 2012, 55, 1817–1830. DOI: 10.1021/jm2013248.
   PubMed Web of Science ®Google Scholar
• Andreani, A.; Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M. Synthesis and Antitubercular Activity of Imidazo[2,1-b]thiazoles. Eur. J. Med. Chem. 2001, 36, 743–746. DOI: 10.1016/s0223-5234(01)01266-1.
   PubMed Web of Science ®Google Scholar
• Beena; Rawat, D. S. Antituberculosis Drug Research: A Critical Overview. Med. Res. Rev. 2013, 33, 693–764. DOI: 10.1002/med.21262.
   PubMed Web of Science ®Google Scholar
• Ghattas, A. E.-B. A. G.; Khodairy, A.; Moustafa, H. M.; Hussein, B. R. M. New Heterocyclic Compounds Derived from 4,6-Diamino-3-cyano-2-methylthiopyridine and Their Biological Activity. J. Heterocycl. Chem. 2017, 54, 879–888. DOI: 10.1002/jhet.2649.
   Web of Science ®Google Scholar
• Chougala, B. M.; Samundeeswari, S.; Holiyachi, M.; Naik, N. S.; Shastri, L. A.; Dodamani, S.; Jalalpure, S.; Dixit, S. R.; Joshi, S. D.; Sunagar, V. A. Microwave Synthesis of Coumarinyl Substituted Pyridine Derivatives as Potent Anticancer Agents and Molecular Docking Studies. ChemistrySelect 2017, 2, 5234–5242. DOI: 10.1002/slct.201700358.
   Web of Science ®Google Scholar
• Prasanthi, G.; Prasad, K. V. S. R. G.; Bharathi, K. Synthesis, Anticonvulsant Activity and Molecular Properties Prediction of Dialkyl 1-(Di(ethoxycarbonyl)methyl)-2,6-dimethyl-4-substituted-1,4-dihydropyridine-3,5-dicarboxylates. Eur. J. Med. Chem. 2014, 73, 97–104. DOI: 10.1016/j.ejmech.2013.12.001.
   PubMed Web of Science ®Google Scholar
• Frolova, L. V.; Malik, I.; Uglinskii, P. Y.; Rogelj, S.; Kornienko, A.; Magedov, I. V. Multicomponent Synthesis of 2,3-Dihydrochromeno[4,3-d]pyrazolo[3,4-b]Pyridine1,6-diones: A Novel Heterocyclic Scaffold with Antibacterial Activity. Tetrahedron. Lett. 2011, 52, 6643–6645. DOI: 10.1016/j.tetlet.2011.10.012.
   PubMed Web of Science ®Google Scholar
• Mahmoud, M. R.; El-Shahawi, M. M.; Abu El-Azm, F. S.; Abdeen, M. Synthesis and Antimicrobial Activity of Polyfunctionally Substituted Heterocyclic Compounds Derived from 5-Cinnamoylamino-2-cyanomethyl-1,3,4-thiadiazole. J. Heterocycl. Chem. 2017, 54, 2352–2359.
   Web of Science ®Google Scholar
• Jiao, Y.; Xin, B.-T.; Zhang, Y.; Wu, J.; Lu, X.; Zheng, Y.; Tang, W.; Zhou, X. Design, Synthesis and Evaluation of Novel 2-(1H-imidazol-2-yl) Pyridine Sorafenib Derivatives as Potential BRAF Inhibitors and Anti-Tumor Agents. Eur. J. Med. Chem. 2015, 90, 170–183. DOI: 10.1016/j.ejmech.2014.11.008.
   PubMed Web of Science ®Google Scholar
• Gueiffier, A.; Mavel, S.; Lhassani, M.; Elhakmaoui, A.; Snoeck, R.; Andrei, G.; Chavignon, O.; Teulade, J.-C.; Witvrouw, M.; Balzarini, J.; et al. Synthesis of Imidazo[1,2-a]pyridines as Antiviral Agents. J. Med. Chem. 1998, 41, 5108–5112. DOI: 10.1021/jm981051y.
   PubMed Web of Science ®Google Scholar
• Ruzziconi, R.; Buonerba, F. Recent Advances in the Synthesis of Regioselectively Fluorinated Homo- and Heterocyclic Compounds by Complementary Cyclization Methods. J. Fluorine Chem. 2013, 152, 12–28. DOI: 10.1016/j.jfluchem.2013.05.001.
   Web of Science ®Google Scholar
• Böhm, H.-J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. Fluorine in Medicinal Chemistry. Chembiochem 2004, 5, 637–643. DOI: 10.1002/cbic.200301023.
   PubMed Web of Science ®Google Scholar
• Swallow, S. Fluorine in Medicinal Chemistry. Prog. Med. Chem. 2015, 54, 65–133. DOI: 10.1016/bs.pmch.2014.11.001.
   Google Scholar
• Kirk, K. L. Fluorination in Medicinal Chemistry: Methods, Strategies, and Recent Developments. Org. Process Res. Dev. 2008, 12, 305–321. DOI: 10.1021/op700134j.
   Web of Science ®Google Scholar
• Chambers, R. D. Fluorine in Organic Chemistry, 2nd ed.; Blackwell: Oxford, 2004.
   Google Scholar
• Service, R. F. Synthetic Biology. Fluorine-Adding Bacteria May Transform Natural Product Medicines. Science 2013, 341, 1052–1053. DOI: 10.1126/science.341.6150.1052-a.
   Web of Science ®Google Scholar
• Khunt, R. C.; Khedkar, V. M.; Chawda, R. S.; Chauhan, N. A.; Parikh, A. R.; Coutinho, E. C. Synthesis, Antitubercular Evaluation and 3D-QSAR Study of N-Phenyl-3-(4-fluoro phenyl)-4-substituted Pyrazole Derivatives. Bioorg. Med. Chem. Lett. 2012, 22, 666–678. DOI: 10.1016/j.bmcl.2011.10.059.
   PubMed Web of Science ®Google Scholar
• Manvar, A.; Khedkar, V.; Patel, J.; Vora, V.; Dodia, N.; Patel, G.; Coutinho, E.; Shah, A. Synthesis and Binary QSAR Study of Antitubercular Quinolylhydrazides. Bioorg. Med. Chem. Lett. 2013, 23, 4896–4902. DOI: 10.1016/j.bmcl.2013.06.076.
   PubMed Web of Science ®Google Scholar
• Rode, N. D.; Sonawane, A. D.; Nawale, L.; Khedkar, V. M.; Joshi, R. A.; Likhite, A. P.; Sarkar, D.; Joshi, R. R. Synthesis, Biological Evaluation, and Molecular Docking studies of Novel 3-Aryl-5-(alkyl-thio)-1H-1,2,4-triazoles Derivatives Targeting Mycobacterium tuberculosis. Chem. Biol. Drug. Des. 2017, 90, 1206–1214.
   PubMed Web of Science ®Google Scholar
• Radadiya, A.; Khedkar, V.; Bavishi, A.; Vala, H.; Thakrar, S.; Bhavsar, D.; Shah, A.; Coutinho, E. Synthesis and 3D-QSAR Study of 1,4-Dihydropyridine Derivatives as MDR Cancer Reverters. Eur. J. Med. Chem. 2014, 74, 375–387. DOI: 10.1016/j.ejmech.2014.01.011.
   PubMed Web of Science ®Google Scholar
• Desai, N. C.; Kotadiya, G. M.; Trivedi, A. R.; Khedkar, V. M.; Jha, P. C. Design, Synthesis, and Biological Evaluation of Novel Fluorinated Pyrazole Encompassing Pyridyl 1,3,4-Oxadiazole Motifs. Med. Chem. Res. 2016, 25, 2698–2717. DOI: 10.1007/s00044-016-1683-y.
   Web of Science ®Google Scholar
• Desai, N. C.; Kotadiya, G. M.; Trivedi, A. R. Studies on Molecular Properties Prediction, Antitubercular and Antimicrobial Activities of Novel Quinoline Based Pyrimidine Motifs. Bioorg. Med. Chem. Lett. 2014, 24, 3126–3130. DOI: 10.1016/j.bmcl.2014.05.002.
   PubMed Web of Science ®Google Scholar
• Desai, N. C.; Trivedi, A. R.; Somani, H. C.; Bhatt, K. A. Design, Synthesis, and Biological Evaluation of 1,4-dihydropyridine Derivatives as Potent Antitubercular Agents. Chem. Biol. Drug. Des. 2015, 86, 370–377. DOI: 10.1111/cbdd.12502.
   PubMed Web of Science ®Google Scholar
• Desai, N. C.; Trivedi, A. R.; Khedkar, V. M. Preparation, Biological Evaluation and Molecular Docking Study of Imidazolyl Dihydropyrimidines as Potential Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors. Bioorg. Med. Chem. Lett. 2016, 26, 4030–4035. DOI: 10.1016/j.bmcl.2016.06.082.
   PubMed Web of Science ®Google Scholar
• Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. J. Immunol. Methods 1983, 65, 55–63. DOI: 10.1016/0022-1759(83)90303-4.
   PubMed Web of Science ®Google Scholar
• Ciapetti, G.; Cenni, E.; Pratelli, L.; Pizzoferrato, A. In Vitro Evaluation of Cell/Biomaterial Interaction by MTT Assay. Biomaterials 1993, 14, 359–364. DOI: 10.1016/0142-9612(93)90055-7.
   PubMed Web of Science ®Google Scholar
• Sreekanth, D.; Syed, A.; Sarkar, S.; Sarkar, D.; Santhakumari, B.; Ahmad, A.; Khan, I. Production, Purification and Characterization of Taxol and 10DAB III from a New Endophytic Fungus Gliocladium sp. Isolated from the Indian Yew Tree, Taxus baccata. J. Microbiol. Biotechnol. 2009, 19, 1342–1347. DOI: 10.4014/jmb.0904.4041.
   PubMed Web of Science ®Google Scholar
• Magnet, S.; Hartkoorn, R. C.; Székely, R.; Pató, J.; Triccas, J. A.; Schneider, P.; Szántai-Kis, C.; Őrfi, L.; Chambon, M.; Banfi, D.; Bueno,, M.; Turcatti, G.; Kéri, G.; Cole, S. T. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis 2010, 90, 354–360. DOI: 10.1016/j.tube.2010.09.001.
   PubMed Web of Science ®Google Scholar
• Kuete, V. Potential of Cameroonian Plants and Derived Products against Microbial Infections: A Review. Planta Med. 2010, 76, 1479–1491. DOI: 10.1055/s-0030-1250027.
   PubMed Web of Science ®Google Scholar
• Singh, R.; Nawale, L. U.; Arkile, M.; Shedbalkar, U. U.; Wadhwani, S. A.; Sarkar, D.; Chopade, B. A. Chemical and Biological Metal Nanoparticles as Antimycobacterial Agents: A Comparative Study. Int. J. Antimicrob. Agents 2015, 46, 183–188. DOI: 10.1016/j.ijantimicag.2015.03.014.
   PubMed Web of Science ®Google Scholar
• Hartkoorn, R. C.; Chandler, B.; Owen, A.; Ward, S. A.; Bertel Squire, S.; Back, D. J.; Khoo, S. H. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis, 2007, 87, 248–255.
   PubMed Web of Science ®Google Scholar
• Asgaonkar, D. K.; Mote, D. G.; Chitre, S. T. QSAR and Molecular Docking Studies of Oxadiazole-Ligated Pyrrole Derivatives as Enoyl-ACP (CoA) Reductase Inhibitors. Sci. Pharm. 2014, 82, 71–85. DOI: 10.3797/scipharm.1310-05.
   PubMedGoogle Scholar
• Kini, S. G.; Bhat, A. R.; Bryant, B.; Williamson, J. S.; Dayan, F. E. Synthesis, Antitubercular Activity and Docking Study of Novel Cyclic Azole Substituted Diphenyl Ether Derivatives. Eur. J. Med. Chem. 2009, 44, 492–500. DOI: 10.1016/j.ejmech.2008.04.013.
   PubMed Web of Science ®Google Scholar
• Mathew, B.; Suresh, J.; Mathew, G. E.; Sonia, G.; Krishnan, G. K. Design, Synthesis, Toxicity Estimation and Molecular Docking Studies of N-(Furan-2-yl)-1-(5-substituted) phenyl-1,3,4-oxadiazol-2-yl) methanimine as Antitubercular Agents. Indian J. Pharm. Sci. 2014, 76, 401–406.
   PubMed Web of Science ®Google Scholar
• Vilchèze, C.; Morbidoni, H. R.; Weisbrod, T. R.; Iwamoto, H.; Kuo, M.; Sacchettini, J. C.; Jacobs, W. R. Inactivation of the InhA-Encoded Fatty Acid Synthase II (FASII) Enoyl-Acyl Carrier Protein Reductase Induces Accumulation of the FASI End Products and Cell Lysis of Mycobacterium smegmatis. J. Bacteriol. 2000, 182, 4059–4067. DOI: 10.1128/jb.182.14.4059-4067.2000.
   PubMed Web of Science ®Google Scholar
• Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. J. Med. Chem. 2004, 47, 1750–1759. DOI: 10.1021/jm030644s.
   PubMed Web of Science ®Google Scholar
• Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; et al. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. J. Med. Chem. 2004, 47, 1739–1749. DOI: 10.1021/jm0306430.
   PubMed Web of Science ®Google Scholar
• Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein−Ligand Complexes. J. Med. Chem. 2006, 49, 6177–6196. DOI: 10.1021/jm051256o.
   PubMed Web of Science ®Google Scholar